| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
61,660,000 |
| Market
Cap: |
48.17(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6394 - $2.39 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile AlloVir is a late clinical-stage cell therapy company developing allogeneic T-cell therapies to treat and prevent devastating viral diseases. Co.'s Pipeline includes: Posoloeucel, which is an allogeneic, off-the-shelf virus-specific T cell (VST) therapy candidate targeting adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus that can lead to devastating viral disease in the allogeneic hematopoietic cell transplant population; and ALVR106, which is an allogeneic, off-the-shelf VST therapy candidate developed to target devastating diseases caused by human metapneumovirus, influenza, parainfluenza virus and respiratory syncytial virus.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
2,930,870 |
| Total Buy Value |
$0 |
$0 |
$0 |
$10,990,763 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
51,312 |
101,127 |
269,585 |
1,510,325 |
| Total Sell Value |
$38,075 |
$76,604 |
$215,316 |
$9,707,840 |
| Total People Sold |
4 |
4 |
4 |
7 |
| Total Sell Transactions |
20 |
40 |
71 |
121 |
| End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Van Beek Jeroen B |
Chief Commercial Officer |
• – – |
2021-02-02 |
4 |
S |
$41.19 |
$2,014,603 |
D/D |
(48,910) |
510,730 |
|
- |
|
| Melian Agustin |
Chief Medical Officer |
• – – |
2021-02-02 |
4 |
S |
$41.19 |
$2,259,230 |
D/D |
(54,849) |
520,266 |
|
- |
|
| Hallal David |
Chief Executive Officer |
• • • |
2021-01-21 |
4 |
A |
$0.00 |
$0 |
D/D |
147,000 |
2,230,666 |
|
- |
|
| Hagen Brett R |
Chief Accounting Officer |
• – – |
2021-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
17,500 |
71,676 |
|
- |
|
| Van Beek Jeroen B |
Chief Commercial Officer |
• – – |
2021-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
559,640 |
|
- |
|
| Leen Ann M. |
Chief Scientific Officer |
• – – |
2021-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
28,000 |
28,000 |
|
- |
|
| Sinha Vikas |
See Remarks |
• • – |
2021-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
58,800 |
865,407 |
|
- |
|
| Atillasoy Ercem |
See Remarks |
• – – |
2021-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
28,000 |
106,500 |
|
- |
|
| Melian Agustin |
Chief Medical Officer |
• – – |
2021-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
43,750 |
575,115 |
|
- |
|
| Miller Edward |
General Counsel |
• – – |
2021-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
28,000 |
194,051 |
|
- |
|
| Miller Edward |
General Counsel |
• – – |
2020-12-01 |
4 |
GA |
$0.00 |
$0 |
I/I |
41,514 |
198,811 |
|
- |
|
| Miller Edward |
General Counsel |
• – – |
2020-12-01 |
4 |
GD |
$0.00 |
$0 |
D/D |
41,514 |
166,051 |
|
- |
|
| Leen Ann M. |
Chief Scientific Officer |
• – – |
2020-11-30 |
4 |
GA |
$0.00 |
$0 |
I/I |
60,394 |
60,394 |
|
- |
|
| Leen Ann M. |
Chief Scientific Officer |
• – – |
2020-11-30 |
4 |
GD |
$0.00 |
$0 |
D/D |
60,394 |
0 |
|
- |
|
| Jovan-Embiricos Morana |
Director |
– • • |
2020-08-03 |
4 |
B |
$17.00 |
$49,300,000 |
I/I |
2,900,000 |
2,800,000 |
2.25 |
- |
|
| Jovan-Embiricos Morana |
Director |
– • • |
2020-08-03 |
4 |
A |
$0.00 |
$0 |
I/I |
15,479,398 |
411,685 |
|
- |
|
| Bornstein Jeffrey S |
Director |
– • – |
2020-08-03 |
4 |
A |
$0.00 |
$0 |
I/I |
20,583 |
20,583 |
|
- |
|
| Wilson John Robert |
Director |
– • – |
2020-08-03 |
4 |
A |
$0.00 |
$0 |
I/I |
2,347,999 |
5,562,954 |
|
- |
|
| Wilson John Robert |
Director |
– • – |
2020-08-03 |
4 |
A |
$0.00 |
$0 |
D/D |
3,184,758 |
3,214,955 |
|
- |
|
| Miller Edward |
General Counsel |
• – – |
2020-08-03 |
4 |
A |
$0.00 |
$0 |
I/I |
32,759 |
32,759 |
|
- |
|
| Vera Juan |
Director |
– • – |
2020-08-03 |
4 |
A |
$0.00 |
$0 |
D/D |
2,436,773 |
2,466,970 |
|
- |
|
| Leen Ann M. |
Chief Scientific Officer |
• – – |
2020-08-03 |
4 |
A |
$0.00 |
$0 |
I/I |
2,436,773 |
2,436,773 |
|
- |
|
| Brainard Diana |
Director |
– • – |
2020-08-03 |
4 |
B |
$17.00 |
$107,100 |
D/D |
6,300 |
6,300 |
2.39 |
- |
|
| Elevatebio, Llc |
10% Owner |
– – • |
2020-08-03 |
4 |
A |
$0.00 |
$0 |
D/D |
13,420,970 |
13,420,970 |
|
- |
|
| Hagen Brett R |
Chief Accounting Officer |
• – – |
2020-08-03 |
4 |
A |
$0.00 |
$0 |
D/D |
4,361 |
54,176 |
|
- |
|
324 Records found
|
|
Page 12 of 13 |
|
|
0.01 (1.47%) 
